Clinical investigation of anti-CD19 Chimeric Antigen Receptor T Cells (PZ01) for relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma

Trial Profile

Clinical investigation of anti-CD19 Chimeric Antigen Receptor T Cells (PZ01) for relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs PZ 01 (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms 2017002
  • Most Recent Events

    • 27 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top